Ep. 132: “Tumor-Infiltrating B Cells” Featuring Dr. Tullia Bruno
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Ep. 132: “Tumor-Infiltrating B Cells” Featuring Dr. Tullia Bruno” inside PodZeus.
Tumor-infiltrating B cells are no longer just passive antibody producers—they're emerging as critical orchestrators of anti-tumor immunity, shaping the tumor microenvironment and enhancing T-cell function through tertiary lymphoid structures (TLS). Dr. Tulia Bruno, a former T-cell immunologist turned B-cell convert, reveals that these structures, once overlooked in subcutaneous mouse models, are now recognized as vital prognostic indicators in human cancers, especially in 'cold' tumors like renal cell carcinoma and sarcoma. Her research shows that TLS formation is not uniform—germinal center-containing TLS are the most beneficial, but their presence depends on tumor location, disease stage, and even the host’s microbiome. Crucially, spatial context matters: B cells don’t act in isolation. Advanced tools like spatial transcriptomics have revealed that cellular positioning—whether near stroma, T cells, or tumor cells—dictates function. This insight is driving a new wave of therapeutics: companies are now developing TLS-inducing drugs and devices, with several in early clinical trials. The implications extend beyond cancer, offering fresh perspectives on autoimmune diseases where TLS thrive in tissues like the brain and kidneys. Bruno’s personal philosophy—'be you, think outside the box'—reflects a field in transformation, where rethinking long-held assumptions about B cells is unlocking new paths in immunotherapy.
Tumor-infiltrating B cells are not just antibody factories but key orchestrators of anti-tumor immunity by forming tertiary lymphoid structures (TLS) that enhance T-cell function.
Germinal center-containing TLS are the most prognostically beneficial, especially in 'cold' tumors like renal cell carcinoma and sarcoma, but their formation depends on tumor location and disease stage.
Spatial context is critical: B cells' function is determined by their position within the tumor microenvironment, requiring tools like spatial transcriptomics to understand their interactions.
TLS formation is not reliably modeled in subcutaneous mouse tumors—orthotopic or carcinogen-induced models (like the NNK lung model) are more physiologically relevant for studying TLS dynamics.
Several companies are now developing TLS-inducing therapeutics (e.g., Mestag Therapeutics’ anti-lipotoxin beta antibody, Galvanized Therapeutics’ osmotic pressure device) in early clinical trials.
…and 3 more takeaways available in PodZeus
Introduction and Sponsorship
The episode opens with hosts Dr. Jason Goldsmith and Dr. Brenda Raut introducing the podcast and welcoming Dr. Tulia Bruno. Sponsorship is announced for Stem Cell Technologies, offering a free EV isolation kit sample for labs.
Conference Reflections and Immune Metabolism
The hosts reflect on their recent conference experience, with Jason admitting he attended only four talks due to back-to-back meetings. They then discuss a Nature paper showing that postprandial chylomicrons enhance T-cell fitness through AKT/mTOR signaling, boosting effector function without transcriptional changes.
T-Cell Priming and Chemokine Regulation
The hosts cover a study showing that CCR7 ligands (CCL19/CCL21) limit T-cell priming duration in lymph nodes by triggering detachment from dendritic cells after 10–24 hours. This brief stimulation prevents exhaustion and enhances long-term T-cell function.
Maternal Helminth Infection and Offspring Immunity
A microbiome paper reveals that subclinical maternal helminth infection alters the maternal microbiome, leading to increased production of indole-3-propionic acid (IPA), which induces interferon signaling in lung epithelial cells and protects offspring from RSV and influenza.
Next-Gen CAR T-Cell Therapy
A phase I trial shows that enriching for stem cell memory CD8+ T cells (CD62L+ CD45RA+) before CAR T-cell production leads to better expansion, lower toxicity (especially CRS), and comparable efficacy with 10-fold fewer cells infused.
“do not use subcutaneous tumors to study B cells and TLS. It will give you a false indication, I think of what's going on within”
“you. and be creative, and think outside the box. And always think about how you could make a difference and how you could think about a question differently,”
“There are therapeutics for inducing TLS and on our lab from all the human work we've done in the mouse modeling, we're now also building our own TLS inducing therapeutics.”
Hosts
Guest
Dr. Tulia Bruno
person
Stem Cell Technologies
organization
NNK model
other
University of Pittsburgh
organization
B cells in cancer consortium
organization
Nature
other
Mestag Therapeutics
organization
Galvanized Therapeutics
organization
National Cancer Institute
organization
Leibniz Institute for Immunotherapy
organization
Ep. 128: “Lymphatic Immunobiology” Featuring Dr. Amanda Lund
The Immunology Podcast • 1h 21m • 4/7/2026
IMMUNOLOGY2026™: Day 1
The Immunology Podcast • 18m • 4/16/2026
IMMUNOLOGY2026™: Day 2
The Immunology Podcast • 26m • 4/17/2026
IMMUNOLOGY2026™: Day 3
The Immunology Podcast • 23m • 4/18/2026
IMMUNOLOGY2026™: Day 4
The Immunology Podcast • 16m • 4/19/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Ep. 132: “Tumor-Infiltrating B Cells” Featuring Dr. Tullia Bruno” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime